470 related articles for article (PubMed ID: 30462965)
21. [The bacille Calmette-Guérin vaccine may reduce the general child morbidity].
Nissen TN; Thøstesen LM; Birk NM; Pihl G; Kjærgaard J; Stensballe LG
Ugeskr Laeger; 2014 Apr; 176(9):. PubMed ID: 25096560
[TBL] [Abstract][Full Text] [Related]
22. Economic Evaluation of Selective Neonatal Bacillus Calmette-Guérin Vaccination of High-risk Infants in Ireland.
Teljeur C; Moran PS; Harrington P; Butler K; Corcoran B; O'Donnell J; Usher C; O'Flanagan D; Connolly K; Ryan M
Pediatr Infect Dis J; 2018 Aug; 37(8):759-767. PubMed ID: 29432385
[TBL] [Abstract][Full Text] [Related]
23. Protective effect of Bacillus Calmette-Guerin (BCG) vaccination in children with extra-pulmonary tuberculosis, but not the pulmonary disease. A case-control study in Rosario, Argentina.
Bonifachich E; Chort M; Astigarraga A; Diaz N; Brunet B; Pezzotto SM; Bottasso O
Vaccine; 2006 Apr; 24(15):2894-9. PubMed ID: 16434130
[TBL] [Abstract][Full Text] [Related]
24. Oral bacillus Calmette-Guérin vaccine against tuberculosis: why not?
Monteiro-Maia R; Pinho RT
Mem Inst Oswaldo Cruz; 2014 Sep; 109(6):838-45. PubMed ID: 25317714
[TBL] [Abstract][Full Text] [Related]
25. Neonatal and infant immunity for tuberculosis vaccine development: importance of age-matched animal models.
Ramos L; Lunney JK; Gonzalez-Juarrero M
Dis Model Mech; 2020 Sep; 13(9):. PubMed ID: 32988990
[TBL] [Abstract][Full Text] [Related]
26. The influence of bacille Calmette-Guerin vaccine strain on the immune response against tuberculosis: a randomized trial.
Ritz N; Dutta B; Donath S; Casalaz D; Connell TG; Tebruegge M; Robins-Browne R; Hanekom WA; Britton WJ; Curtis N
Am J Respir Crit Care Med; 2012 Jan; 185(2):213-22. PubMed ID: 22071384
[TBL] [Abstract][Full Text] [Related]
27. Novel tuberculosis vaccination strategies based on understanding the immune response.
Kaufmann SH
J Intern Med; 2010 Apr; 267(4):337-53. PubMed ID: 20433580
[TBL] [Abstract][Full Text] [Related]
28. The effect of Bacille Calmette-Guérin vaccine on tuberculin reactivity in indigenous children from communities with high prevalence of tuberculosis.
Araujo Z; de Waard JH; de Larrea CF; Borges R; Convit J
Vaccine; 2008 Oct; 26(44):5575-81. PubMed ID: 18723065
[TBL] [Abstract][Full Text] [Related]
29. Effectiveness of the Bacillus Calmette-Guerin vaccine in an Indonesian population with D543N NRAMP1 polymorphism.
Putera I; Pakasi TA; Syahmar I; Bramantyo AA; Karyadi E; Melani A; Sahiratmadja E
J Infect Dev Ctries; 2015 Jan; 9(1):42-7. PubMed ID: 25596570
[TBL] [Abstract][Full Text] [Related]
30. Current perspective in tuberculosis vaccine development for high TB endemic regions.
Husain AA; Daginawala HF; Singh L; Kashyap RS
Tuberculosis (Edinb); 2016 May; 98():149-58. PubMed ID: 27156631
[TBL] [Abstract][Full Text] [Related]
31. Epidemiology of childhood tuberculosis after ceasing universal Bacillus Calmette-Guérin vaccination.
Kobayashi S; Yoshiyama T; Uchimura K; Hamaguchi Y; Kato S
Sci Rep; 2021 Aug; 11(1):15902. PubMed ID: 34354146
[TBL] [Abstract][Full Text] [Related]
32. BCG vaccination strategies against tuberculosis: updates and perspectives.
Qu M; Zhou X; Li H
Hum Vaccin Immunother; 2021 Dec; 17(12):5284-5295. PubMed ID: 34856853
[TBL] [Abstract][Full Text] [Related]
33. Vaccination strategies to prevent tuberculosis in the new millennium: from BCG to new vaccine candidates.
Franco-Paredes C; Rouphael N; del Rio C; Santos-Preciado JI
Int J Infect Dis; 2006 Mar; 10(2):93-102. PubMed ID: 16377228
[TBL] [Abstract][Full Text] [Related]
34. Prime-boost vaccination with Bacillus Calmette Guerin and a recombinant adenovirus co-expressing CFP10, ESAT6, Ag85A and Ag85B of Mycobacterium tuberculosis induces robust antigen-specific immune responses in mice.
Li W; Li M; Deng G; Zhao L; Liu X; Wang Y
Mol Med Rep; 2015 Aug; 12(2):3073-80. PubMed ID: 25962477
[TBL] [Abstract][Full Text] [Related]
35. Prevention of M. tuberculosis Infection with H4:IC31 Vaccine or BCG Revaccination.
Nemes E; Geldenhuys H; Rozot V; Rutkowski KT; Ratangee F; Bilek N; Mabwe S; Makhethe L; Erasmus M; Toefy A; Mulenga H; Hanekom WA; Self SG; Bekker LG; Ryall R; Gurunathan S; DiazGranados CA; Andersen P; Kromann I; Evans T; Ellis RD; Landry B; Hokey DA; Hopkins R; Ginsberg AM; Scriba TJ; Hatherill M;
N Engl J Med; 2018 Jul; 379(2):138-149. PubMed ID: 29996082
[TBL] [Abstract][Full Text] [Related]
36. Can immunization with Bacillus Calmette-Guérin be improved for prevention or therapy and elimination of chronic
Alvarez AH; Flores-Valdez MA
Expert Rev Vaccines; 2019 Dec; 18(12):1219-1227. PubMed ID: 31826664
[No Abstract] [Full Text] [Related]
37. Protective efficacy of neonatal Bacillus Calmette-Guérin vaccination against tuberculosis.
Sirinavin S; Chotpitayasunondh T; Suwanjutha S; Sunakorn P; Chantarojanasiri T
Pediatr Infect Dis J; 1991 May; 10(5):359-65. PubMed ID: 2067885
[TBL] [Abstract][Full Text] [Related]
38. Estimating the effect of the 2005 change in BCG policy in England: a retrospective cohort study, 2000 to 2015.
Abbott S; Christensen H; Welton NJ; Brooks-Pollock E
Euro Surveill; 2019 Dec; 24(49):. PubMed ID: 31822330
[TBL] [Abstract][Full Text] [Related]
39. The current status, challenges, and future developments of new tuberculosis vaccines.
Gong W; Liang Y; Wu X
Hum Vaccin Immunother; 2018 Jul; 14(7):1697-1716. PubMed ID: 29601253
[TBL] [Abstract][Full Text] [Related]
40. Divergent effect of bacillus Calmette-Guérin (BCG) vaccination on Mycobacterium tuberculosis infection in highly related macaque species: implications for primate models in tuberculosis vaccine research.
Langermans JA; Andersen P; van Soolingen D; Vervenne RA; Frost PA; van der Laan T; van Pinxteren LA; van den Hombergh J; Kroon S; Peekel I; Florquin S; Thomas AW
Proc Natl Acad Sci U S A; 2001 Sep; 98(20):11497-502. PubMed ID: 11562492
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
